Methods and compositions for treating or preventing erythema
View Patent ↗Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
1. A method of treating erythema or a symptom associated therewith in a subject, the method comprising topically administering to a skin area of the subject a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one a adrenergic receptor agonist and a pharmaceutically acceptable carrier, wherein the skin area is, or is prone to be, affected by the erythema or the symptom associated therewith.
2. The method of claim 1 , wherein the erythema is erythema of rosacea.
3. The method of claim 1 , wherein the at least one α-adrenergic receptor agonist is an agonist selective for an α1-adrenergic receptor.
4. The method of claim 1 , wherein the at least one α-adrenergic receptor agonist is an agonist selective for an α2-adrenergic receptor.
5. The method of claim 1 , wherein the at least one α-adrenergic receptor agonist is a non-selective α-adrenergic receptor agonist.
6. The method of claim 1 , wherein the at least one α-adrenergic receptor agonist is brimonidine.
7. The method of claim 1 , wherein the at least one α-adrenergic receptor agonist is oxymetazoline.
8. The method of claim 1 , wherein the at least one α-adrenergic receptor agonist is naphazoline.
9. The method of claim 1 , wherein the at least one α-adrenergic receptor agonist is selected from the group consisting of tetrahydrozoline, xylometazoline, phenylephrine, methoxamine, mephentermine, metaraminol, midodrine, epinephrine and norepinephrine.
10. The method of claim 1 , further comprising administering to the subject at least one additional treatment and medication for erythema or the symptom associated therewith.
11. The method of claim 1 , wherein the topical aqueous gel composition is administered to the skin area once daily.
12. The method of claim 1 , wherein the topical aqueous gel composition comprises about 0.20% (w/w) to about 4.0% (w/w) gelling agent.
13. The method of claim 1 , wherein the topical aqueous gel composition comprises about 0.50% (w/w) to about 2.0% (w/w) carbomer.